Federal district courts can’t allow the FTC to reclaim profits from companies that benefited from unfair competition, the Third Circuit ruled in a case over AbbVie’s control of a testosterone gel patent.
The appeals court Wednesday reversed a district court decision ordering AbbVie and Besins Healthcare Inc. to pay $448 million for allegedly filing sham patent lawsuits to stifle competition.
Section 13(b) of the FTC Act doesn’t give courts the power to order disgorgement, which would enable the Federal Trade Commission to claw back money from companies engaged in anticompetitive behavior, the U.S. Court of Appeals for the Third Circuit ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.